These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 883324

  • 21. [Urinary hydroxyproline and cancer of the breast].
    Bellido V, Carda P, Mascías E.
    Rev Esp Oncol; 1983; 30(1):7-16. PubMed ID: 6679910
    [No Abstract] [Full Text] [Related]

  • 22. Bone collagen and calcium metabolism in normocalcemic and hypercalcemic patients with breast cancer.
    Lee CA, Lloyd HM.
    Cancer; 1971 May; 27(5):1099-105. PubMed ID: 5092517
    [No Abstract] [Full Text] [Related]

  • 23. Hydroxyproline excretion in malignant neoplastic disease.
    Hosley HF, Taft EG, Olson KB, Gates S, Beebe RT.
    Arch Intern Med; 1966 Dec; 118(6):565-71. PubMed ID: 5925444
    [No Abstract] [Full Text] [Related]

  • 24. Proceedings: Urinary hydorxyproline excretion in the monitoring of carcinoma of the breast.
    Lester E.
    Br J Radiol; 1976 Mar; 49(579):290. PubMed ID: 1276611
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The postabsorptive hydroxyproline in the long-term evaluation of patients with breast cancer.
    Niell HB, Neely CL, Palmieri GM, McDonald MW.
    Cancer; 1983 Oct 15; 52(8):1442-7. PubMed ID: 6616407
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastases, and patients with primary hyperparathyroidism.
    Stĕpán JJ, Mikulecký M, Bek V, Broulík P, Pacovský V.
    Neoplasma; 1989 Oct 15; 36(4):495-501. PubMed ID: 2770935
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Hydroxyproline in generalized bone diseases].
    Czitober H, Raab W.
    Dtsch Med J; 1970 Jun 20; 21(12):857-64. PubMed ID: 5512354
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Hydroxyproline in the early diagnosis of bone metastases in prostatic cancer.
    Kontturi MJ, Sotaniemi EA, Larmi TK.
    Scand J Urol Nephrol; 1974 Jun 20; 8(2):91-5. PubMed ID: 4366246
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Relation between urine zinc and hydroxyproline in rheumatoid arthritis and bone diseases.
    Ambanelli U, Ferraccioli GF, Bernardi P, Servemti G.
    J Rheumatol; 1978 Jun 20; 5(4):477-9. PubMed ID: 739496
    [No Abstract] [Full Text] [Related]

  • 37. [Urinary polyamines and hydroxyproline in patients with breast cancer].
    Solov'ev IE, Iurzhenko NN.
    Vrach Delo; 1986 Jun 20; (6):80-4. PubMed ID: 3750970
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
    Kurokawa K, Imai K, Yamanaka H, Tomaru Y, Kitaura K.
    Hinyokika Kiyo; 1985 Dec 20; 31(12):2119-25. PubMed ID: 2421558
    [Abstract] [Full Text] [Related]

  • 40. Urinary hydroxyproline excretion and survival in cancer of the breast.
    Cuschieri A.
    Clin Oncol; 1975 Jun 20; 1(2):127-30. PubMed ID: 1183101
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.